John Cumbers authored an article featuring Alok Tayi’s new start-up, Vibe Bio.
“In short, the contours of drug development are defined around inflection points — the kinds of milestones that serve as “power-ups” to move a company to the next level of funding and scientific research by increasing a company’s valuation and strategically informing what the path forward can and should look like. Inflection points that are often most under the microscope occur before drugs enter Phase 2 or 3 clinical trials, covering terrain often referred to as the “valley of death.”
“Tayi is a scientist with a background in materials science and extensive experience in the biotech industry — among the speakers at this week’s upcoming SynBioBeta conference. After a postdoc with Harvard scientist George Whitesides, he went on to found a series of software companies with a focus on the life sciences and over $100 million in venture funding.”
“However, the one thing these experiences did not reveal is the extent to which the obstacles around developing treatments aren’t necessarily discovering them, but instead are funding them.”
